Pyxis Oncology (PYXS) Non Operating Investment Income (2023 - 2025)
Pyxis Oncology (PYXS) reported Non Operating Investment Income of -$16000.0 for Q4 2025, up 91.16% year-over-year from -$8369.9 in Q4 2024, and down 121.62% on a QoQ basis from $74000.0 in Q3 2025.
Pyxis Oncology (PYXS) has 3 years of Non Operating Investment Income data on file, last reported at -$16000.0 in Q4 2025.
- Quarterly Non Operating Investment Income rose 91.16% year-over-year to -$16000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$117000.0 (down 209.35% YoY) and the FY2025 annual result came in at -$117000.0, down 209.35% from the prior year.
- Non Operating Investment Income declined to -$16000.0 in Q4 2025 per PYXS's latest filing, from $74000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $696000.0 in Q1 2023 and bottomed at -$781000.0 in Q2 2023.
- The 3-year median for Non Operating Investment Income is -$31000.0 (2023), against an average of $4416.7.
- Peak annual rise in Non Operating Investment Income reached 2365.0% in 2024, while the deepest fall reached 207.74% in 2024.
- Tracing PYXS's Non Operating Investment Income over 3 years: stood at $168000.0 in 2023, then sank by 207.74% to -$181000.0 in 2024, then surged by 91.16% to -$16000.0 in 2025.
- Per Business Quant, the three latest PYXS Non Operating Investment Income figures stand at -$16000.0 (Q4 2025), $74000.0 (Q3 2025), and -$54000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn | -16,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16,000.00 |
| Dec 31, 2025 | -16,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Jun 30, 2025 | -54,000.00 |
| Jun 30, 2025 | -54,000.00 |
| Mar 31, 2025 | -121,000.00 |
| Mar 31, 2025 | -121,000.00 |
| Dec 31, 2024 | -181,000.00 |
| Dec 31, 2024 | -181,000.00 |
| Sep 30, 2024 | 453,000.00 |
| Sep 30, 2024 | 453,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Mar 31, 2024 | -123,000.00 |
| Mar 31, 2024 | -123,000.00 |
| Dec 31, 2023 | 168,000.00 |
| Dec 31, 2023 | 168,000.00 |
| Sep 30, 2023 | -20,000.00 |
| Sep 30, 2023 | -20,000.00 |
| Jun 30, 2023 | -781,000.00 |
| Jun 30, 2023 | -781,000.00 |
| Mar 31, 2023 | 696,000.00 |
| Mar 31, 2023 | 696,000.00 |